Hong Kong could become biotech listing hub, says BeiGene boss

Hong Kong could become biotech listing hub, says BeiGene boss

Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation The cancer treatment firm is the first to seek a secondary listing in the city since the bourse overhauled its rules in a bid to attract big technology companies Hong Kong's stock exchange could become a hub for mainland biotechnology firms thanks to a sweeping reform of listing rules, said the boss of BeiGene, the first such company to take advantage of the new regime for a secondary listing.

from Biotech News